We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

17 hedge funds and large institutions have $35.5M invested in Krystal Biotech in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

42% more funds holding

Funds holding: 12 → 17 (+5)

15% more capital invested

Capital invested by funds: $31M → $35.5M (+$4.5M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6.65% less ownership

Funds ownership: 29.84% → 23.18% (-6.7%)

Holders
17
Holders Change
+5
Holders Change %
+41.67%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$410K
2
JP Morgan Chase
JP Morgan Chase
New York
+$240K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$116K
4
Millennium Management
Millennium Management
New York
+$96.3K
5
BlackRock
BlackRock
New York
+$63.1K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$5M
2
HCM
Highbridge Capital Management
New York
-$2.6M
3
TCP
Tourbillon Capital Partners
New York
-$530K

KRYS Hedge Fund Activity: Q2 2018 in Review

17 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2018, worth a combined $35.5M — up 15% from $31M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new KRYS positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $410K. The largest seller was RA Capital Management, exiting entirely with an estimated $5M sold.

  • 17 institutional investors held Krystal Biotech (KRYS) as of Q2 2018, up from 12 in Q1 2018.
  • Funds reported $35.5M of Krystal Biotech stock for Q2 2018, up 15% quarter-over-quarter.
  • 6 funds opened new Krystal Biotech positions in Q2 2018 and 1 closed out, a net change of +5 holders.
  • The largest Krystal Biotech buyer in Q2 2018 was Geode Capital Management, an estimated $410K added.
  • The largest Krystal Biotech seller in Q2 2018 was RA Capital Management, an estimated $5M sold.

Based on aggregated 13F filings for Q2 2018.